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Pathology of the lung in myositis
Epidemiology of lung involvement in autoimmune myositis
Th  e interstitial lung diseases (ILDs) encompass a large 
number of distinct disorders that are characterized by 
inﬂ  ammation and/or ﬁ  brosis involving the lung paren-
chyma. Th   ese disorders result from a myriad of potential 
etiologies including medications, environmental exposures 
and autoimmune diseases such as myositis. Regardless of 
etiology, these lung injuries result in a limited number of 
patterns that are classiﬁ  ed based on pathologic appear-
ance into several major subgroups (Table 1). In general, 
the pathology impacts prognosis regard  less of the 
etiology of the ILD. Th  e target of injury includes the 
critical alveolar–capillary interface respon  sible for gas 
exchange. As a group, therefore, ILDs result in com-
promised oxygen absorption as well as decreased lung 
compliance and increased work of breathing. Th  e  clinical 
manifestation of ILD is typically dyspnea on exertion, 
cough and fatigue.
Lung involvement in autoimmune myositis was ﬁ  rst 
systematically reviewed in 1974 [1], although it had been 
described in individuals and case series since the mid-
1960s. Since that time, there has been an increasing 
appreciation of the prevalence and clinical signiﬁ  cance of 
ILD. Recent studies suggest that ILD complications occur 
in 20 to 65% of individuals with myositis (reviewed in 
[2]). Th   e wide variation in prevalence reﬂ  ects in part the 
lack of a standard approach to screening for ILD in newly 
diagnosed patients with myositis. A recent study of 90 
histidyl-tRNA synthetase (Jo-1) patients found ILD 
present in 86% [3]. Alanyl-tRNA synthetase (PL-12) is 
similarly associated with ILD in 90% or more of patients 
based on two recent case series [4,5]. Th  e apparently 
increasing rates of ILD in patients with myositis represent 
a combi  nation of improved diagnostic techniques and 
increasing awareness of ILD as a presenting symptom of 
auto  immune myositis. Th   e mortality associated with ILD 
has been anecdotally described since the earliest reports. 
Prospective long-term studies suggest a 40% increase in 
mortality attributable to ILD [6]. ILD is thus both a 
common and a highly lethal manifestation of auto-
immune myositis.
Cellular and cytokine makeup of the normal and injured 
lung
Th  e normal alveolus has a simple cellular makeup with 
resident alveolar type I cells arranged along a basement 
membrane lining the alveolar airspaces. Type II cells 
occupy the corners of the alveoli and are the source of 
type I cells in the event of cellular damage. Surrounding 
the alveoli are ﬁ  ne capillary networks lined by endothelial 
cells. Th   e alveolar–capillary interface is a dynamic barrier. 
Inﬂ   ammatory cells including neutrophils, lympho  cytes 
and macrophages travel through the capillary vessels and 
transit into the alveolar air space. Mature ﬁ  broblasts and 
circulating ﬁ  brocytes can also transit through the alveolar 
basement membrane. Resident antigen-presenting cells, 
including dendritic cells, serve as key sensors for danger 
signaling and are principally responsible for inﬂ  ammatory 
cell inﬂ  ux.
Abstract
Interstitial lung disease is a common manifestation 
of autoimmune myositis that confers signifi  cant 
morbidity and mortality. The vulnerability of the lung 
may off  er insight into the etiology of this autoimmune 
disease. The frequency and patterns of lung injury 
vary based on the autoantibody. Antibodies against 
the aminoacyl-tRNA synthetases and melanoma 
diff  erentiation-induced gene-5 are frequently 
associated with interstitial lung disease. Although 
the mechanisms underlying these associations have 
not been fully elucidated, emerging data highlight 
the importance of autoantigen expression and 
conformation in the target tissue (lung and muscle, 
in this case), as well as identifying relevant amplifying 
pathways (such as regeneration).
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much like the skin, it is in a permanent state of cellular 
injury and regeneration. Under normal circum  stances, 
type I cells are generated by type II cells and injury does 
not result in ﬁ  brosis. In the setting of more severe injury, 
or in certain vulnerable hosts, injured type I cells are 
instead replaced by ﬁ   broblasts, possibly from marrow-
derived circulating ﬁ  brocytes. Th   e constant cycle of injury 
and repair in the lung creates a unique opportunity for the 
development of neoantigens, which is compounded by the 
frequency of viral encounters in the lung. Indeed, there 
have been a number of studies that associate the presence 
of ILD with speciﬁ  c viral pathogens [7-9].
Patterns of lung injury in myositis
A number of pathologic patterns are associated with 
myositis ILD. Th  e most common patterns documented 
by surgical lung biopsy in a recent study of Jo-1-asso-
ciated ILD showed diﬀ  use alveolar damage in 55%, usual 
interstitial pneumonia in 45% and nonspeciﬁ  c interstitial 
pneumonia in 14% [3]. Interestingly, the diagnoses based 
on chest CT patterns rather than tissue biopsy favored a 
preponderance of nonspeciﬁ   c interstitial pneumonia 
(50%) while only 30% of CTs were suggestive of usual 
inter  stitial pneumonia. Th  is high prevalence of diﬀ  use 
alveolar damage on surgical biopsy probably reﬂ  ects a 
tendency toward performing biopsies in patients who are 
failing therapy or who present with acute interstitial 
pneumonia as a ﬁ   rst manifestation of myositis. In a 
recent multicenter series of patients with PL-12, 45% of 
patients had either biopsy or CT consistent with usual 
interstitial pneumonia, 16% with nonspeciﬁ  c interstitial 
pneumonia and 16% with cryptogenic organizing 
pneumonia [4]. Th   e pattern of lung injury in myositis ILD 
thus appears to span the spectrum, but with a higher 
frequency of usual interstitial pneumonia than is 
commonly seen in other autoimmune ILDs.
Unique clinical patterns associated with interstitial lung 
disease
While myositis is traditionally deﬁ  ned by the presence of 
muscle or skin inﬂ  ammation, it is increasingly apparent 
that a subset of patients with myositis-associated anti-
bodies presents either initially or uniquely with ILD. Th  is 
pattern has been highlighted by patients with clinically 
amyopathic dermatomyositis (CADM), with rapidly 
progressive and frequently fatal ILD (reviewed in [10]). 
Th   ese patients might previously have been con  sidered to 
have idiopathic acute interstitial pneumonia. However, 
increasing awareness of CADM and the dis  covery of 
additional autoantibodies associated with this clinical 
presentation (see below) will allow more accurate 
ascertainment of this presentation. Th  e occurrence of 
such a dramatic pulmonary-centric presentation raises 
the question of whether the primary site of injury might 
in fact be the lung rather than the muscle.
Prominent autoantibody specifi  cities found in 
patients with myositis and lung disease
Across the spectrum of rheumatic autoimmune diseases, 
distinct patterns of antibody reactivity are strongly 
associated with speciﬁ  c clinical subgroups – a feature 
that makes autoantibodies of diagnostic and prognostic 
use. For example, autoantibodies against topoisomerase I 
are found in patients with diﬀ  use scleroderma and lung 
disease, whereas antibodies against centromere protein B 
are found in patients with limited scleroderma and are 
predictive of digit loss. In patients with idiopathic inﬂ  am-
matory myopathies, such associations are also found. A 
well-recognized example of this is the strong association 
of myositis-speciﬁ   c anti-aminoacyl-tRNA synthetase 
(anti-ARS) antibodies with ILD. Interestingly, emerging 
data from another recently described dermatomyositis 
(DM)-speciﬁ   c antibody – melanoma diﬀ  erentiation-
induced gene-5 (MDA-5) – indicates that it is also asso-
ciated with ILD. Details of these two distinct myositis-
speciﬁ  c autoantibody types are discussed below.
Aminoacyl-tRNA synthetase autoantibodies
ARSs are ubiquitously expressed, highly conserved cyto-
plasmic enzymes that perform an essential cellular 
function: they catalyze the esteriﬁ  cation of speciﬁ  c amino 
acids to their cognate tRNA, thus forming an aminoacyl-
tRNA complex. Th   ere is a distinct ARS for each of the 20 
Table 1. Pathologic patterns in interstitial lung disease
Pattern Pathologic  fi  ndings  Associated outcome
Acute interstitial pneumonia  Diff  use alveolar damage with hyaline membrane   >90% mortality at 30 days
 formation
Cryptogenic organizing pneumonia or   Intraluminal fi  bromyxoid tissue in the terminal and  Good response to steroids
bronchiolitis obliterans with organizing   respiratory bronchioles 
pneumonia  
Nonspecifi  c interstitial pneumonia  Temporally and spatially homogeneous infl  ammatory   Good response except with fi  brosing variant
  injury with and without fi  brosis
Usual interstitial pneumonia  Temporally heterogeneous, subpleural infl  ammatory   Less responsive to immunosuppressant therapies
  injury with fi  brosis and honeycombing
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acid to an elongating polypeptide chain as the ribosome 
transcribes the coding sequence of mRNA into the 
appro  priate protein. To date, autoantibodies to eight of 
the ARS enzymes have been identiﬁ   ed; these include 
antibodies against histidyl-tRNA synthetase (Jo-1) [11], 
alanyl-tRNA synthetase (PL-12) [12], threonyl-tRNA 
synthetase (PL-7) [13], glycyl-tRNA synthetase (EJ) [14], 
isoleucyl-tRNA synthetase (OJ) [14], asparaginyl-tRNA 
synthetase (KS) [15], phenylalanyl-tRNA synthetase (Zo) 
[16] and tyrosyl-tRNA synthetase (YRS) [17]. Of these, 
anti-Jo-1 is by far the most frequently found speciﬁ  city, 
occurring in 15 to 20% of myositis patients, whereas the 
other anti-ARS autoantibodies are found in 1 to 4% of 
myositis patients [18]. Although anti-ARS antibodies 
may be found together with other antibodies in some 
patients (for example, frequently with Ro52), it is note-
worthy and intriguing that individuals with anti-ARS 
antibodies rarely target more than a single synthetase.
Anti-ARS antibodies are associated with a distinct 
clinical syndrome referred to as the antisynthetase syn-
drome. Characteristic features (shown in Figure 1) 
include myositis, ILD, nonerosive arthritis, Raynaud’s 
phenomenon, fever and mechanic’s hands (hyperkeratotic 
lesions along the radial and palmar aspects of the ﬁ  ngers) 
[19]. While clinical similarities between patients with 
diﬀ  erent ant-ARSs are striking, noteworthy distinctions 
between these patient groups have been described.
For example, Kalluri and colleagues recently reported a 
detailed analysis of the clinical features of 31 subjects 
with anti-PL-12 antibodies [4]. Th  ey found a higher 
frequency of ILD in these patients compared with those 
with Jo-1 antibodies (90% versus 50 to 75%), whereas the 
association with myositis/myalgia was less strong (52% 
versus 90%). Th  ese ﬁ   ndings are consistent with those 
reported by other workers, including a large study of 
Japanese myositis patients with anti-ARS antibodies 
performed by Yoshifuji and colleagues [20]. In addition to 
the clinical experience linking anti-ARS antibodies with 
lung pathology, a mouse model of anti-Jo-1 immune 
response demonstrates predominant lung disease [21]. 
Th   is study as well as others correlating anti-Jo1 antibody 
levels with disease activity [22] raise the possibility that 
anti-ARS antibodies are pathogenic. However, this 
remains to be resolved. For years it has been noted that a 
signiﬁ   cant proportion of myositis patients have ILD 
without autoantibodies [2], raising the possibility of 
additional speciﬁ  cities that are as yet unidentiﬁ  ed. Recent 
ﬁ   ndings show that this may indeed be the case: new 
myositis-speciﬁ   c antibodies continue to be described 
[23], including MDA-5 (see below), which was also 
recently found to associate with ILD. Of interest, these 
Figure 1. Characteristic features of antisynthetase syndrome.
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ARS antibodies.
Melanoma diff  erentiation-induced gene-5 antibodies
MDA-5 antibodies were ﬁ  rst described in 2005 by Sato 
and colleagues in a study of 103 adult Japanese myositis 
patients (seen at Keio University in Tokyo) [24]. At the 
time, these antibodies were named anti-CADM-140 
because they recognized a 140 kDa protein in patients 
and were associated with CADM; the antibodies were 
found in 8/42 (19%) DM patients and in 0/61 (0%) poly-
myositis patients, with all eight of the antibody-positive 
patients having CADM. In this study, the authors 
reported that the presence of these antibodies was 
associated with rapidly progres  sive ILD, with 50% of the 
antibody-positive patients having ILD compared with 6% 
in the antibody-negative group [24]. Th   ese authors sub-
se quently  identiﬁ   ed the 140 kDa autoantigen as a 
cytoplasmic RNA helicase encoded by MDA-5 [25]. Th  is 
protein is a known RNA virus receptor, thus potentially 
providing a mechanistic linkage between the develop-
ment of myositis ILD and viral infection [26].
Th  ese ﬁ  ndings have been validated by those of Naka-
shima and colleagues, who independently and almost 
simultaneously identiﬁ  ed the CADM-140 autoantigen as 
MDA-5 [27]. Th  ey studied an adult Japanese patient 
cohort seen at Kyoto University Hospital. Eighty-four 
myositis patients were studied, and anti-MDA-5 anti-
bodies were found in 13/37 (35%) and 0/47 (0%) of DM 
patients and polymyositis patients, respectively. Of those 
patients with the antibody, 2/13 had typical DM and 
11/13 had CADM. Interestingly, 54% of the anti-MDA-5-
positive group had rapidly progressive ILD compared 
with 4% of the anti-MDA-5-negative sera, consistent with 
the ﬁ  ndings of Sato and colleagues [24].
Gono and colleagues evaluated the clinical features of 
patients with MDA-5 antibodies and compared them 
with those of patients with anti-ARS antibodies in a 
retro  spective study (at Tokyo Women’s Medical 
University) [28]. Th  ey identiﬁ  ed 65 patients with DM/
CADM, 46 (71%) of whom also had ILD. Amongst this 
latter group, 24/46 (52%) had either anti-MDA-5 or anti-
ARS antibodies. Interesting diﬀ  erences were noted when 
clinical features of the 14 anti-MDA-5-positive patients 
were compared with the 10 anti-ARS-positive patients. 
In the former group, the frequency of acute/subacute 
interstitial pneumonia was signiﬁ  cantly higher (71% com-
pared with 20%), the cumulative 60-month survival rate 
was lower (63% versus 100%), serum ferritin levels were 
higher (680 ng/ml versus 171 ng/ml) and the median 
creatinine kinase values were lower (198 IU compared 
with 1,513 IU). While the numbers in the groups are 
small, making caution necessary in drawing conclusions, 
these ﬁ   ndings indicate that serum ferritin levels and 
MDA-5 antibodies may be useful indicators for the early 
diagnosis of acute/subacute interstitial pneu  monia with 
DM. It is also noteworthy that all three of the above 
studies showed that MDA-5 antibodies are found 
exclusively in patients with DM.
New data continue to expand the clinical phenotype 
associated with MDA-5 autoantibodies. For example, 
ﬁ  nd  ings from a recent study of DM patients seen at the 
Stanford University Department of Dermatology out-
patient clinic [29] show that the presence of anti-MDA-5 
antibodies is associated with very distinctive cutaneous 
ulcerations and palmar papules. In this cohort, MDA-5 
antibodies also identiﬁ  ed a population of DM patients at 
increased risk for rapid lung disease (22.2% in the anti-
MDA-5-positive DM group versus 4.5% in the anti-
MDA-5-negative group). Identifying antibodies against 
MDA-5 in DM patients is therefore of clinical impor-
tance, as this speciﬁ  city associates with high risk of ILD – 
including rapidly progressing ILD, which can lead to 
patient mortality, as well as cutaneous ulcerations and 
palmar papules. To date, there are no commercial assays 
that can be used to identify these antibodies in the 
clinical setting. Additionally, as mentioned above, it is 
noteworthy that other as yet unidentiﬁ  ed autoantibodies 
probably do exist in patients with idiopathic inﬂ  am  ma-
tory myopathies and ILD that are at present classiﬁ  ed as 
antibody-negative. Identiﬁ  cation of these antibodies may 
well yield further ﬁ  ne speciﬁ  city of use for predicting and 
monitoring distinct clinical subgroups within the spec-
trum of DM patients with lung disease. Additional 
studies are also needed to understand why antigens as 
apparently unrelated as ARS and MDA-5 are such 
speciﬁ   c targets of the autoimmune response in this 
disease spectrum. Interestingly, several recent reports 
link anti-polymyositis Scl antibody with a similar pheno-
type to that of the antisynthetase syndrome [30,31]. Th  e 
mechanism underlying such similarity is unclear, but 
might include a shared HLA type or other shared genetic 
factors.
Mechanisms regulating expression of ARS and 
MDA-5
While the mechanisms underlying the association of 
immune responses against speciﬁ  c, ubiquitously expressed 
autoantigens with distinct clinical disease pheno  types 
remain undeﬁ  ned, emerging data are focus  ing attention 
on unique expression patterns of the myositis-speciﬁ  c 
autoantigens themselves. Th  us, although most auto  anti-
gens are ubiquitously expressed, recent in vivo ﬁ  ndings 
show that signiﬁ  cant diﬀ  erences in expression levels exist 
in unique microenvironments. Th  ese concepts are well 
illustrated by the examples of ARS and MDA-5, as des-
cribed below. Such ﬁ  ndings of local elevated expression 
levels of speciﬁ   c antigens are of great potential 
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targeted in speciﬁ  c autoimmune diseases, and why the 
feed-forward loop of autoimmunity is propagated so 
eﬀ  ectively.
Elevated levels of ARS are expressed in normal lung and 
regenerating muscle cells
Important new insights into the in vivo expression of 
autoantigens in unique microenvironments within rele-
vant target tissues themselves were made several years 
ago [32]. While these studies indicate a probable role for 
damaged muscle in initiating/propagating myositis, they 
do not address the role of lung; however, the emerging 
principles may well be applicable to the lung, and are 
therefore reviewed brieﬂ  y below. Th   e authors performed 
immunoblots on lysates made from control and myositis 
patient muscle biopsies. Unexpectedly, the data showed 
very low expressed levels of myositis autoantigens such 
as the ARSs in control muscle. In contrast, these 
autoantigens were robustly expressed in lysates made 
from muscle biopsies obtained from myositis patients. 
Immunohistochemical studies conﬁ   rmed that the 
enhanced autoantigen expression was detected in muscle 
cells themselves, as well as in inﬁ  ltrating inﬂ  ammatory 
cells. Importantly, further characterization of the muscle 
cell staining conﬁ   rmed that the enhanced autoantigen 
expression was found in the regenerating muscle cells, 
and not in mature myotubes. Th  ese  ﬁ  ndings demonstrate 
that mature, healthy muscle is probably not the target of 
autoimmunity. Instead, injured muscle in which re-
generat  ing muscle cells (expressing high levels of 
mysoitis-speciﬁ   c autoantigens such as the ARS mole-
cules) are replacing injured cells may be the primary 
target. Th  e direction of the immune response against 
regenerating muscle cells, critical participants in the 
healing of muscle injury, probably enables a feed-forward 
cycle where tissue damage drives antigen expression, 
immune response and additional tissue damage.
Little is currently known about autoantigen expression 
in lung. Th  e limited data examining levels of myositis-
speciﬁ  c autoantigens in the lung available to date provide 
tantalizing evidence that levels of Jo-1 are increased in 
normal lung relative to the two other normal tissues that 
were studied (muscle and breast), and that Jo-1 expres-
sion in normal lung is robust whereas expression of other 
myositis autoantigens is minimal (Mi-2 and the catalytic 
subunit of DNA-dependent protein kinase were the other 
two autoantigens examined) [32]. Future studies will be 
important to evaluate whether and which cells in the lung 
express altered myositis autoantigen levels. Th  e  regenera-
tion of alveolar type I cells from type II cells mirrors the 
regeneration of myocytes from muscle satellite cells in 
some aspects, thus providing a potentially analogous 
model for antigen upregulation in the lung.
In addition to autoantigen levels, the autoantigen 
structure plays a critical role in shaping the immune 
response. Changes in autoantigen structure in response 
to immune eﬀ  ector pathways are particularly relevant to 
autoimmune tissue injury. Noteworthy in this regard are 
the structural changes (including generation of novel 
cleavage fragments) induced when target cells are killed 
by the cytotoxic lymphocyte granule exocytosis pathway. 
Granzyme B is a protease that is abundantly expressed in 
cytotoxic lymphocyte granules. Th   is essential host 
defense mechanism is mediated by cytotoxic lympho-
cytes and natural killer cells, and has been documented 
to exist in myositis tissues [33]. Many myositis auto-
antigens (including Jo-1) are cleaved by granzyme B [34]. 
Interestingly, a novel form of Jo-1 that is more susceptible 
to cleavage by granzyme B in the human lung has been 
demonstrated [35], raising the possibility that novel Jo-1 
cleavage fragments might be generated uniquely in the 
lung. Th   is would result in distinct fragments and 
consequently cryptic epitope generation during antigen 
processing.
Of note, the cleavable Jo-1 conformation was not 
detected in muscle, thus focusing attention on the lung as 
the possible initiation site for anti-ARS autoimmunity 
associated with ILD. In this scenario, muscle might 
become targeted at a later stage, potentially in the setting 
of later muscle damage, where muscle regeneration 
induces high levels of Jo-1 – and other myositis-speciﬁ  c 
autoantigen – expression and autoimmune injury. It is of 
some interest that Jo-1 has been shown to trigger chemo-
kine receptors on T cells and immature dendritic cells 
[36], raising a possible mechanistic association between 
increased antigen expression and inﬂ  ammatory  cell 
recruit  ment. Whether cleavage of Jo-1 enhances its eﬀ  ect 
on chemokine receptors is not currently known. Further 
studies examining the expression and cleavability in 
both the lung and muscle of other ARS molecules and 
MDA-5 are needed to provide additional context and 
interpretation.
Substantial evidence has accumulated implicating type 
I interferons in the pathogenesis of DM [37]. It is note-
worthy that both MDA-5 and Ro52 – frequent targets in 
DM – are type I interferon inducible. Evaluating whether 
MDA-5 expression is increased in target tissues in DM 
(lung, muscle and skin) with the ARS/ILD disease 
spectrum will be informative. Such observations may 
suggest a potential role for anti-interferon therapies in 
MDA-5-associated lung disease.
Whether autoantibodies have a direct role in generating 
and augmenting tissue injury in myositis-associated ILD 
is very unclear, but there are no available data to support 
this role. Rather, it is more likely that autoantibody 
speciﬁ  cities reﬂ  ect the antigen driving a T-cell response, 
which more directly results in tissue injury. Data about 
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myositis are not available, but there are several intriguing 
studies suggesting that the fulminant onset of ILD 
associated with myositis is linked to the increased CD8 T 
cells in the lung that express cytotoxic properties [38,39]. 
Th   ere are some interesting, although anecdotal, data that 
suggest treatment of such patients with the T-cell-
directed agents cyclosporine or FK506 may have a 
beneﬁ  cial eﬀ  ect [40,41]. Deﬁ  ning antigen-speciﬁ  c CD4 
and CD8 T cells in the lung of patients with myositis and 
ILD may provide very important insights into the 
mechanism and possibly therapy in these diseases.
Models for targeting the lung in myositis
Two distinct models currently exist, which diﬀ  er in the 
initiation site, that may explain the targeting of the lung 
in patients with myositis.
One scenario is that the lung is the primary target of 
the autoimmune response. Here, the presence of supra-
threshold levels of Jo-1 or MDA-5 potentially during 
infection or malignancy may produce novel autoantigen 
forms. In the setting of an appropriate immune response, 
autoreactivity to these novel antigens may be produced. 
In the setting of subsequent muscle injury (for example, 
muscle overuse or viral infection), the preformed 
immune response might be directed against regenerating 
muscle cells that express high levels of myositis auto-
antigens, thereby focusing the subsequent ampliﬁ  cation 
loop onto muscle.
An alternate model would invoke muscle as the primary 
target, with the lung being involved as a bystander. In this 
circumstance, enhanced expression of myositis 
autoantigens could be caused by muscle damage with 
increased numbers of regenerating cells, or as a 
consequence of interferon exposure. Th  e subsequent 
immune response may become focused on the lung, where 
relevant myositis autoantigens are robustly expressed.
Conclusion
Th  e striking targeting of the lung in autoimmune 
myopathies that are associated with speciﬁ  c autoantibody 
responses (noteworthy examples include MDA-5 and the 
ARS family of antigens) provides important pathogenic 
insights. Understanding antigen expression, confor  ma-
tions and modiﬁ  cations in the lung is key to deﬁ  ning 
relevant mechanisms. Whether involvement of the lung 
in this disease spectrum occurs because it is the primary 
target or the secondary target of the autoimmune 
response is currently unknown, but identifying ampli-
fying pathways (for example, interferon or regeneration) 
may have therapeutic implications.
Abbreviations
ARS, aminoacyl-tRNA synthetase; CADM, clinically amyopathic 
dermatomyositis; CT, computed tomography; DM, dermatomyositis; ILD, 
interstitial lung disease; Jo-1, histidyl-tRNA synthetase; MDA-5, melanoma 
diff  erentiation-induced gene-5; PL-12, alanyl-tRNA synthetase.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
The present work was supported by National Institutes of Health grant 
AR44684 (to LC-R) and by the Lisa Sandler Spaeth and Robert M. Fisher Funds 
for Pulmonary Fibrosis (to SKD). Images in Figure 1 were used with permission 
from Dr Christopher-Stine.
Author details
1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, 
Baltimore, MD 21224, USA. 2Division of Rheumatology, Johns Hopkins 
University, Baltimore, MD 21224, USA.
Published: 13 July 2011
References
1.  Frazier AR, Miller RD: Interstitial pneumonitis in association with 
polymyositis and dermatomyositis. Chest 1974, 65:403-407.
2.  Labirua A, Lundberg IE: Interstitial lung disease and idiopathic 
infl  ammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010, 
22:633-638.
3.  Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, Fertig 
N, Oddis CV, Kaminski N, Rosas IO, Ascherman DP: Characterization and 
peripheral blood biomarker assessment of anti-Jo-1 antibody-positive 
interstitial lung disease. Arthritis Rheum 2009, 60:2183-2192.
4.  Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff   SK, 
Casciola-Rosen L, Hong G, Dellaripa PF, Highland KB: Clinical profi  le of anti-
PL-12 autoantibody. Cohort study and review of the literature. Chest 2009, 
135:1550-1556.
5.  Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, Camara B, 
Fournie B, Couret B, Hatron PY, Dubucquoi S, Hamidou M: Clinical 
manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA 
synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. 
Rheumatology (Oxford) 2010, 49:972-976.
6.  Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, 
Ternamian PJ, Cordier JF; Groupe d’Etudes et de Recherche sur les Maladies 
‘Orphelines’ Pulmonaires: Interstitial lung disease in amyopathic 
dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 2003, 
22:245-250.
7.  Crowson AN, Magro CM, Dawood MR: A causal role for parvovirus B19 
infection in adult dermatomyositis and other autoimmune syndromes. 
J Cutan Pathol 2000, 27:505-515.
8.  Kasifoglu T, Korkmaz C, Ozkan R: Cytomegalovirus-induced interstitial 
pneumonitis in a patient with dermatomyositis. Clin Rheumatol 2006, 
25:731-733.
9.  Weidensaul D, Imam T, Holyst MM, King PD, McMurray RW: Polymyositis, 
pulmonary fi  brosis, and hepatitis C. Arthritis Rheum 1995, 38:437-439.
10.  Sato S, Kuwana M: Clinically amyopathic dermatomyositis. Curr Opin 
Rheumatol 2010, 22:639-643.
11.  Nishikai M, Reichlin M: Heterogeneity of precipitating antibodies in 
polymyositis and dermatomyositis. Characterization of the Jo-1 antibody 
system. Arthritis Rheum 1980, 23:881-888.
12.  Bunn CC, Bernstein RM, Mathews MB: Autoantibodies against alanyl-tRNA 
synthetase and tRNAAla coexist and are associated with myositis. J Exp 
Med 1986, 163:1281-1291.
Autoimmune Basis of Rheumatic Diseases
This article is part of a series on Myositis, edited by Ingrid Lundberg, 
which can be found online at 
http://arthritis-research.com/series/myositis
This series forms part of a special collection of reviews covering major 
autoimmune rheumatic diseases, available at: 
http://arthritis-research.com/series/abrd
Danoff   and Casciola-Rosen Arthritis Research & Therapy 2011, 13:230 
http://arthritis-research.com/content/13/4/230
Page 6 of 713.  Mathews MB, Reichlin M, Hughes GR, Bernstein RM: Anti-threonyl-tRNA 
synthetase, a second myositis-related autoantibody. J Exp Med 1984, 
160:420-434.
14. Targoff   IN: Autoantibodies to aminoacyl-transfer RNA synthetases for 
isoleucine and glycine. Two additional synthetases are antigenic in 
myositis. J Immunol 1990, 144:1737-1743.
15.  Hirakata M, Suwa A, Nagai S, Kron MA, Trieu EP, Mimori T, Akizuki M, Targoff   IN: 
Anti-KS: identifi  cation of autoantibodies to asparaginyl-transfer RNA 
synthetase associated with interstitial lung disease. J Immunol 1999, 
162:2315-2320.
16.  Betteridge Z, Gunawardena H, North J, Slinn J, McHugh N: Anti-synthetase 
syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase 
(anti-Zo) associated with polymyositis and interstitial pneumonia. 
Rheumatology (Oxford) 2007, 46:1005-1008.
17.  Hashish L, Trieu EP, Sadanandan P, Targoff   IN: Identifi  cation of autoantibodies 
to tyrosyl-tRNA synthetase in dermatomyositis with features consistent 
with antisynthetase syndrome [abstract]. Arthritis Rheum 2005, 52:S312.
18.  Hengstman GJ, van Engelen BG, Vree Egberts WT, van Venrooij WJ: Myositis-
specifi  c autoantibodies: overview and recent developments. Curr Opin 
Rheumatol 2001, 13:476-482.
19.  Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport 
MJ: Polymyositis, pulmonary fi  brosis and autoantibodies to aminoacyl-
tRNA synthetase enzymes. Q J Med 1990, 77:1019-1038.
20.  Yoshifuji H, Fujii T, Kobayashi S, Imura Y, Fujita Y, Kawabata D, Usui T, Tanaka M, 
Nagai S, Umehara H, Mimori T: Anti-aminoacyl-tRNA synthetase antibodies 
in clinical course prediction of interstitial lung disease complicated with 
idiopathic infl  ammatory myopathies. Autoimmunity 2006, 39:233-241.
21.  Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, Fertig N, Oury T, 
Vandersteen D, Clemens P, Camacho CJ, Weinberg A, Ascherman DP: 
Species-specifi  c immune responses generated by histidyl-tRNA 
synthetase immunization are associated with muscle and lung 
infl  ammation. J Autoimmun 2007, 29:174-186.
22.  Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, 
Ascherman DP: Anti-Jo-1 antibody levels correlate with disease activity in 
idiopathic infl  ammatory myopathy. Arthritis Rheum 2007, 56:3125-3131.
23.  Gunawardena H, Betteridge ZE, McHugh NJ: Newly identifi  ed 
autoantibodies: relationship to idiopathic infl  ammatory myopathy 
subsets and pathogenesis. Curr Opin Rheumatol 2008, 20:675-680.
24.  Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, Nishikawa T, Oddis 
CV, Ikeda Y: Autoantibodies to a 140-kd polypeptide, CADM-140, in 
Japanese patients with clinically amyopathic dermatomyositis. Arthritis 
Rheum 2005, 52:1571-1576.
25.  Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M: RNA 
helicase encoded by melanoma diff  erentiation-associated gene 5 is a 
major autoantigen in patients with clinically amyopathic 
dermatomyositis: association with rapidly progressive interstitial lung 
disease. Arthritis Rheum 2009, 60:2193-2200.
26.  Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, 
Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e 
Sousa C, Matsuura Y, Fujita T, Akira S: Diff  erential roles of MDA5 and RIG-I 
helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
27.  Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, Kawabata 
D, Ohmura K, Usui T, Fujii T, Okawa K, Mimori T: The RIG-I-like receptor IFIH1/
MDA5 is a dermatomyositis-specifi  c autoantigen identifi  ed by the anti-
CADM-140 antibody. Rheumatology (Oxford) 2010, 49:433-440.
28.  Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, 
Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H: Clinical manifestation 
and prognostic factor in anti-melanoma diff  erentiation-associated gene 5 
antibody-associated interstitial lung disease as a complication of 
dermatomyositis. Rheumatology (Oxford) 2010, 49:1713-1719.
29.  Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L: The 
mucocutaneous and systemic phenotype of dermatomyositis patients 
with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad 
Dermatol 2011, 65:25-34.
30.  Marie I, Lahaxe L, Benveniste O, Delavigne K, Adoue D, Mouthon L, Hachulla E, 
Constans J, Tiev K, Levesque H, Boyer O, Jouen F: Long-term outcome of 
patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J 
Derm 2010, 162:337-344.
31.  Lega JC, Cottin V, Fabien N, Thivolet-Bejui F, Cordier JF: Interstitial lung 
disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase 
autoantibodies: a similar condition? J Rheumatol 2010, 37:1000-1009.
32.  Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, 
Rosen A: Enhanced autoantigen expression in regenerating muscle cells in 
idiopathic infl  ammatory myopathy. J Exp Med 2005, 201:591-601.
33.  Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, 
Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R: Diff  erential 
expression of perforin in muscle-infi  ltrating T cells in polymyositis and 
dermatomyositis. J Clin Invest 1996, 97:2905-2910.
34.  Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A: Cleavage by 
granzyme B is strongly predictive of autoantigen status: implications for 
initiation of autoimmunity. J Exp Med 1999, 190:815-826.
35.  Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, Rosen A, Casciola-
Rosen LA: Novel conformation of histidyl-transfer RNA synthetase in the 
lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis 
Rheum 2007, 56:2729-2739.
36.  Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen 
L, Hartlein M, Kron M, Yang D, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ: 
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens 
in myositis, activate chemokine receptors on T lymphocytes and 
immature dendritic cells. J Exp Med 2002, 196:781-791.
37.  Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn 
RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferon-
alpha/beta-mediated innate immune mechanisms in dermatomyositis. 
Ann Neurol 2005, 57:664-678.
38.  Sauty A, Rochat T, Schoch OD, Hamacher J, Kurt AM, Dayer JM, Nicod LP: 
Pulmonary fi  brosis with predominant CD8 lymphocytic alveolitis and 
anti-Jo-1 antibodies. Eur Respir J 1997, 10:2907-2912.
39.  Yokoyama T, Sakamoto T, Shida N, Kinoshita M, Kunou Y, Karukaya R, 
Takamatsu M, Aizawa H: Fatal rapidly progressive interstitial pneumonitis 
associated with amyopathic dermatomyositis and CD8 T lymphocytes. 
J Intensive Care Med 2005, 20:160-163.
40.  Guglielmi S, Merz TM, Gugger M, Suter C, Nicod LP: Acute respiratory 
distress syndrome secondary to antisynthetase syndrome is reversible 
with tacrolimus. Eur Respir J 2008, 31:213-217.
41.  Takada K, Nagasaka K, Miyasaka N: Polymyositis/dermatomyositis and 
interstitial lung disease: a new therapeutic approach with T-cell-specifi  c 
immunosuppressants. Autoimmunity 2005, 38:383-392.
doi:10.1186/ar3347
Cite this article as: Danoff   SK, Casciola-Rosen L: The lung as a possible target 
for the immune reaction in myositis. Arthritis Research & Therapy 2011, 13:230.
Danoff   and Casciola-Rosen Arthritis Research & Therapy 2011, 13:230 
http://arthritis-research.com/content/13/4/230
Page 7 of 7